- Home
- DCTH vs TMCI Comparison
DCTH vs TMCI Comparison
Compare DCTH & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- TMCI
- Stock Information
- Founded
- DCTH 1988
- TMCI 2014
- Country
- DCTH United States
- TMCI United States
- Employees
- DCTH N/A
- TMCI N/A
- Industry
- DCTH Medical/Dental Instruments
- TMCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DCTH Health Care
- TMCI Health Care
- Exchange
- DCTH Nasdaq
- TMCI Nasdaq
- Market Cap
- DCTH 387.2M
- TMCI 464.4M
- IPO Year
- DCTH N/A
- TMCI 2021
- Fundamental
- Price
- DCTH $10.91
- TMCI $6.98
- Analyst Decision
- DCTH Strong Buy
- TMCI Hold
- Analyst Count
- DCTH 4
- TMCI 7
- Target Price
- DCTH $21.50
- TMCI $7.90
- AVG Volume (30 Days)
- DCTH 375.2K
- TMCI 382.3K
- Earning Date
- DCTH 11-08-2024
- TMCI 11-05-2024
- Dividend Yield
- DCTH N/A
- TMCI N/A
- EPS Growth
- DCTH N/A
- TMCI N/A
- EPS
- DCTH N/A
- TMCI N/A
- Revenue
- DCTH $22,644,000.00
- TMCI $202,861,000.00
- Revenue This Year
- DCTH $1,605.13
- TMCI $13.15
- Revenue Next Year
- DCTH $111.67
- TMCI $8.36
- P/E Ratio
- DCTH N/A
- TMCI N/A
- Revenue Growth
- DCTH 945.91
- TMCI 16.14
- 52 Week Low
- DCTH $3.43
- TMCI $3.92
- 52 Week High
- DCTH $13.30
- TMCI $15.98
- Technical
- Relative Strength Index (RSI)
- DCTH 57.95
- TMCI 44.94
- Support Level
- DCTH $11.67
- TMCI $7.36
- Resistance Level
- DCTH $13.30
- TMCI $7.75
- Average True Range (ATR)
- DCTH 0.73
- TMCI 0.36
- MACD
- DCTH 0.01
- TMCI -0.18
- Stochastic Oscillator
- DCTH 34.60
- TMCI 6.83
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.